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Abstract:
Background:
The 6-aminoquinolone WM5, previously identified by us, is among the most selective small molecules known as TAR RNA binders to show anti-
HIV activity.
Methods:
Starting from WM5, a series of analogues modified at N-1, C-6 or C-7 position was prepared by inserting guanidine or amidine groups as well as
other protonable moieties intended to electrostatically bind the phosphate backbone of TAR. All the compounds were tested for their ability to
inhibit HIV-1 replication in MT-4 cells and in parallel for their cytotoxicity. The active compounds were also evaluated for their ability to interfere
with the formation of the Tat-TAR complex using a Fluorescence Quenching Assay (FQA).
Results:
Some of the synthesized compounds showed an anti-HIV-1 activity in the sub-micromolar range with the naphthyridone derivatives being the most
potent. Three of the synthesized derivatives were able to interact with the Tat-TAR complex formation presenting Ki values improved as compared
to the values obtained with WM5.
Conclusion:
The addition of a pyridine-based protonable side chain at the N-1 position of the quinolone/naphthyridone core imparted to the compounds the
ability to interfere with Tat-TAR complex formation and HIV-1 replication.
Keywords: Anti-HIV quinolones, Tat-mediated transcription inhibitors, Antiviral agents, Medicinal chemistry, WM5, Fluorescence quenching
assay.
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1. INTRODUCTION
In  the  past  decades,  considerable  work has  been done in
exploiting  small  non-coding  hairpin  RNA fragments  as  drug
targets.  However,  compared  with  the  compounds  targeting
proteins, the identification of molecules that selectively bind to
structured RNA motifs remains an important challenge [1 - 3].
One of the most studied RNA structures is the Transactivation
response  element  (TAR)  of  HIV-1  genome  [4  -  9],  a  short
stem-bulge-loop structure located  in  the long  terminal repeat
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Sciences,  University  of  Perugia,  Via  del  Liceo  1,  06123,  Perugia,  Italy;  Tel:
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region at the 5’ end of all nascent HIV-1 transcripts. Its specific
interaction with the HIV-1 regulatory protein Tat is essential
for viral gene expression, replication and pathogenesis [10, 11].
TAR  RNA  is  extremely  conserved  among  viral  isolates
making it a very attractive target. During the last two decades,
many small molecules, aminoglycosides-conjugates, Tat-based
peptidomimetics,  and  peptides  have  been  reported  as  TAR
binders [12 - 19].
Among the small molecules known as TAR RNA binder,
the 6-aminoquinolone WM5 Fig. (1), which was developed in
our lab, inhibits the Tat-mediated transactivation by interfering
selectively with the bulge region of TAR RNA [20].
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Numerous derivatives have been designed and synthesized
starting  from  WM5  with  the  aim  to  gain  Structure-Activity
Relationship  (SAR)  insights,  reduce  the  cytotoxicity  and
further investigate the molecular mechanism of action [21]. As
a consequence, many compounds endowed with good HIV-1
and HIV-2 inhibitory activity in both chronically infected and
acutely infected cells have already been identified. However, a
direct  correlation  between  the  anti-HIV  activity  and  their
ability  to  interfere  with  the  Tat-TAR RNA complex was  not
always observed [22]. On the other hand, when the quinolone
nucleus  lacking  both  C-7  arylpiperazine  and  C-3  carboxylic
functions was properly functionalized with protonable groups
at  the  C-2  position,  a  series  of  2-phenylquinolones  was
obtained  showing  an  improved  ability  to  displace  Tat-TAR
complex but at the expense of antiviral activity [23, 24].
Here,  we  came  back  to  WM5  preparing  a  series  of
analogues designed to enhance its ability to recognize the viral
nucleic  acid  TAR  RNA.  Considering  that  TAR  plays  its
essential role in the Tat-mediated transcription by specifically
binding Tat and that in the Tat-TAR complex the arginine rich
basic  portion  of  Tat  is  responsible  for  the  TAR binding,  we
decided  to  modify  WM5  by  inserting  guanidine  or  amidine
groups as  well  as  other  protonable moieties  intended to bind
electrostatically the phosphate backbone of TAR. In the present
paper, the synthesis of a series of WM5 analogues modified at
N-1, C-6 or C-7 position Fig. (1), and their anti-HIV-1 activity
along with their cytotoxicity in MT-4 cells, are reported. The
active  compounds  were  also  evaluated  in  a  Fluorescence
Quenching Assay (FQA) to determine their ability to interfere
with the formation of the complex between TAR RNA and a
truncated Tat peptide.
1.1. Design of WM5 Analogues
Starting from WM5, the C-6 amino group was replaced by
a more basic guanidine in compound 1, while at C-7 position
an amidine moiety replaced the 2-pyridine ring in compound 2,
and an imidazoline ring was present at the C-4 position of the
pyridine  in  compound  3  Fig.  (1).  Pyridine  and  (pyri-
dinyl)piperazine  moieties  were  inserted  at  the  N-1  position
through methyl, ethyl, or propyl chains, as in compounds 4, 5
[25] and 6, respectively Fig. (1). Moreover, by maintaining the
propyl  chain,  the  piperazine  and  the  pyridine  rings  were
alternatively deleted as in compounds 7 and 8, respectively Fig.
(1).  We  have  previously  reported  that  the  1,8-naphthyridone
nucleus,  when  decorated  with  a  1,3-benzothiazolpiperazine
moiety at the C-7 position, grants potent and selective anti-HIV
activity [26, 27]. Thus, the same flexible protonable side chains
were  also  inserted  at  N-1  position  of  the  1,8-naphthyridone
scaffold, obtaining compounds 9 [25], 10 [25], 11, and 12 Fig.
(1).
2. MATERIALS AND METHODS
2.1. Chemistry
Starting  materials,  reagents,  and  solvents  that  were
commercially available were used as supplied.  The reactions
were monitored by TLC on silica gel 60F254 (Merck) and the
compounds  were  visualized  by  UV  and/or  iodine.  Flash
chromatography columns were performed on Merck silica gel
60  (mesh  230-400).  After  extraction,  organic  solutions  were
dried  using  anhydrous  Na2SO4,  filtered,  and  evaporated  to
dryness at  reduced pressure using a Büchi rotary evaporator.
Yields are of pure products and were not optimized. Melting
points  were  determined  in  capillary  tubes  (Büchi  Elec-
trothermal Mod. 9100) and are uncorrected. Elemental analyses
were  performed  on  a  Fisons  elemental  analyzer,  Model
EA1108CHN, and the data for C, H and N are within ± 0.4% of
the  theoretical  values.  1H  NMR  and  13C  NMR  spectra  were
recorded at 200 MHz (Bruker Avance DPX-200) and 400 MHz
(Bruker  Avance  DRX-400)  using  residual  solvents  such  as
dimethylsulfoxide  (δ  =  2.48)  or  chloroform (δ  =  7.26)  as  an
internal standard. Chemical shifts (δ) are reported in parts per
million (ppm), and peak multiplicity are reported as s (singlet),
d (doublet), t (triplet), q (quartet), p (pentet), hept (heptet), m
(multiplet), or brs (broad singlet). Target compounds 5 [25], 9
[26], 10 [27] have been synthesized as previously reported.
2.1.1.  6-(E)-(2,3-Di-Tert-Butoxyguanidino)-1-Methyl-4-Oxo-
7-[4-(Pyridin2-yl)Piperazin-1-yl]]-1,4-Dihydroquinoline-3-
Carboxylic Acid (13)
To  a  solution  of  WM5  [20]  (0.13  g,  3.29  mmol)  in  dry
DMF (10 mL), Et3N (0.07 g, 7.24 mmol, 0.1 mL), N,N′-di-(tert-
butoxycarbonyl)thiourea (0.10 g, 3.45 mmol), and HgCl2 (cat.
amount)  were  added.  The  mixture  was  reacted  at  room
temperature  for  15  min.  The  solvent  was  subsequently  con-
centrated under vacuum and the residue was treated with EtOH
yielding  a  precipitate  that  was  eliminated  by  filtration.  The
filtrate  was  evaporated  to  dryness  obtaining  a  solid  that  was
washed with hot EtOH (3 times), filtered off, and dried to give
compound  13  (0.10  g,  10%):  mp  >  300  °C;  1H  NMR  (400
MHz,  CDCl3)  δ  1.50  (s,  18H,  CH3),  3.05-3.25  (m,  4H,
piperazine CH2), 3.70-3.90 (m, 7H, CH3 and piperazine CH2),
6.60-6.75 (m, 2H, pyridine CH),  7.05 (s,  1H, H-8),  7.40 (bs,
1H, NH), 7.50 (t, J = 6.0 Hz, 1H, pyridine CH), 8.10 (d, J = 6.0
Hz,  1H,  pyridine  CH),  8.70  (s,  1H,  H-5),  9.40  (s,  1H,  H-2),
10.80 (bs, 1H, NH), 12.40 (s, 1H, COOH).
2.1.2.  6-Guanidino-1-Methyl-4-Oxo-7-(4-(Pyridin2-yl)  Pipe-
razin -1-yl])-1,4-Dihydroquinoline-3-Carboxylic Acid (1)
HCl was bubbled through a solution of compound 13 (0.10
g,  1.74  mmol)  in  a  mixture  of  absolute  EtOH  (10  mL)  and
CHCl3 (10 mL), at room temperature. After 15 h, the obtained
precipitate was collected by filtration, washed with a mixture
of EtOH/CHCl3 (1:1), and dried, to give 1 (0.018 g, 26%): mp
>  300  °C;  1H  NMR  (400  MHz,  DMSO-d6)  δ  3.10-3.25  and
4.10-4.25  (m,  each  4H,  piperazine  CH2),  3.90  (s,  3H,  CH3),
7.00 (t, J = 6.4 Hz, 1H, pyridine CH), 7.30 (s, 1H, H-8), 7.50
(d, J = 9.5 Hz, 1H, pyridine CH), 8.05-8.10 (m, 2H, pyridine
CH), 8.25 (bs, 1H, NH), 8.75 (s, 1H, H-5), 8.90 (s, 1H, H-2),
9.50 (bs, 1H, COOH). Anal. calcd. for C21H22N6O3: C 59.85, H
5.50, N 23.26, found: C 60.00, H 5.75, N 23.00.
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Fig. (1). WM5 analogues characterized by protonable groups.
2.1.3.  Ethyl  7-(4-Carbamidoylpiperazin-1-Yl)-1-Methyl-6-
Nitro-4-Oxo-1,4-Dihydroquinoline-3-Carboxylate (15)
To a solution of synthon 14 [28] (0.70 g, 1.92 mmol) in dry
DMSO (50 mL),  methyl  imidothiocarbamate  sulfate  (0.26  g,
0.959 mmol)  was added.  The reaction mixture was stirred at
120  °C  for  6  h.  After  cooling,  the  precipitate  obtained  was
filtered and dried, to give 15 (0.77 g, 99%): mp 179-181 °C; 1H
NMR  (400  MHz,  DMSO-d6)  δ  1.25  (t,  J  =  7.0  Hz,  3H,
CH2CH3),  3.20-3.30  and  3.60-3.70  (m,  each  4H,  piperazine
CH2),  3.90  (s,  3H,  CH3),  4.25  (q,  J  =  7.0  Hz,  2H,  CH2CH3),
7.15  (s,  1H,  H-8),  8.10  (bs,  3H,  NH  and  NH2),  8.60  (s,  1H,
H-5), 8.70 (s, 1H, H-2).
2.1.4.  6-Amino-7-(4-Carbamidoylpiperazin-1-Yl)-1-Methyl-4-
Oxo-1,4-Dihydroquinoline-3-Carboxylic Acid (2)
To a solution of 15 (0.15 g, 3.69 mmol) in H2O (200 mL)
and  NH4OH conc  (5  mL),  a  solution  of  FeSO4  (0.71  g,  2.58
mmol)  in  the  minimum  amount  of  H2O  was  added  and  the
mixture was stirred at room temperature. After 1 h, the reaction
mixture  was  filtered  over  Celite®  and  the  filtrate  was
evaporated  to  dryness  to  give  a  residue  that  was  crystallized
from  H2O  yielding  ethyl  6-amino-7-(4-carbamimidoyl-
piperazin-1-yl)-1-methyl-4-oxo-1,4-dihydroquinoline-3-carb-
oxylate (0.08 g, 58%), which was used in the next step without
further  purification.  Thus,  ethyl  6-amino-7-(4-carbamimi-
doylpiperazin-1-yl)-1-methyl-4-oxo-1,4-dihydroquino-line-3-
carboxylate (0.08 g, 0.21 mmol) was dissolved in EtOH (3 mL)
and  6N  HCl  (3  mL)  was  added.  The  reaction  mixture  was
stirred at reflux for 7 h. After cooling, the precipitate obtained
was  filtrated,  washed  with  EtOH,  and  purified  by
crystallization from MeOH/DMF, to give 2 (0.013 g, 17%): mp
>  300  °C;  1H  NMR  (400  MHz,  DMSO-d6)  δ  2.90-3.20  and
3.60-3.90  (m,  each  4H,  piperazine  CH2),  3.90  (s,  3H,  CH3),
7.20 (s, 1H, H-8), 7.50 (s, 1H, H-5), 7.90 (bs, 3H, NH e NH2),
8.80 (s, 1H, H-2). Anal. calcd. for C16H20N6O3: C 55.80, H 5.85,
N 24.40, found: C 55.63, H 5.98, N 24.35.
2.1.5.  1-[4-(4,5-Dihydro-1h-Imidazol-2-Yl)Pyridin-2-Yl]Pipe-
razine (18)
A mixture of 16 [29] (0.50 g, 26.1 mmol), ethylenediamine
(0.17 g, 2.87 mmol), and p-toluenesulfonic acid (0.54 g, 2.87
NH
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mmol)  was  reacted  under  reflux  for  3  h.  After  cooling,  the
reaction mixture was diluted with H2O and then extracted with
CHCl3.  The  organic  layers  were  dried  and  evaporated  to
dryness to give 18 (0.40 g, 66%) as an oil; 1H NMR (400 MHz,
DMSO-d6) δ 2.70-2.80 and 3.20-3.30 (m, each 4H, piperazine
CH2), 3.65 (bs, 4H, imidazoline CH2), 3.80 (bs, 1H, NH), 7.00
(d, J  = 5.0 Hz, 1H, pyridine CH), 7.20 (s, 1H, pyridine CH),
8.20 (s, 1H, pyridine CH).
2.1.6.  General  Procedure  for  the  C-7  Nucleophilic
Substitution Reaction (Method A)
A  mixture  of  the  selected  synthon  (1.0  equiv),  the
appropriate  base  (3.0  equiv),  and  K2CO3  (3.0  equiv)  in  dry
DMF  was  stirred  at  40-80°C  until  no  starting  material  was
detected by TLC (2-72 h). After cooling, the reaction mixture
was  poured  into  ice/water  yielding  a  precipitate  which  was
washed with water and then with Et2O, and further purified as
reported in the description of the compounds.
2.1.7.  Ethyl 7-(4-(4-(4,5-Dihydro-1h-Imidazol-2-Yl)Pyridin2-
yl)Piperazin-1-yl])-1-Methyl-6-Nitro-4-Oxo-1,4-
Dihydroquinoline-3-Carboxylate (19)
The title compound was obtained starting from 17 [20] and
18 using Method A (80 °C, 6 h) after crystallization from DMF
in 88% yield: mp 255-256 °C; 1H NMR (400 MHz, DMSO-d6)
δ 1.25 (t,  J  = 7.0 Hz, 3H, CH2CH3),  3.30-3.40 and 3.70-3.75
(m, each 4H, piperazine CH2), 3.80 (bs, 4H, imidazoline CH2),
3.95 (s, 3H, CH3), 4.25 (q, J = 7.0 Hz, 2H, CH2CH3), 7.05 (d, J
= 5.0 Hz, 1H, pyridine CH), 7.10-7.15 (m, 1H, pyridine CH),
7.20 (s, 1H, H-8), 8.20 (d, J = 5.0 Hz, 1H, pyridine CH), 8.55
(s, 1H, H-2), 8.70 (s, 1H, H-5).
2.1.8. General Procedure for Reduction of C-6 Nitro Group
(Method B)
A stirred solution of the selected 6-nitroderivative in DMF
was  hydrogenated  over  a  catalytic  amount  of  Raney  nickel
under  atmospheric  pressure  at  room  temperature  until  no
starting  material  was  detected  by  TLC  (15  min-3  h).  The
mixture  was  then  filtered  over  Celite,  and  the  filtrate  was
evaporated to dryness to afford a residue that was treated with
EtOH/Et2O yielding a solid that was filtered and dried.
2.1.9.  Ethyl  6-Amino-7-(4-(4-(4,5-Dihydro-1h-Imidazol-2-
Yl)Pyridin2-yl)Piperazin-1-yl])-1-Methyl-4-Oxo-1,4-
Dihydroquinoline-3-Carboxylate (20)
The title  compound was  obtained  starting  from 19  using
Method  B  (3  h)  after  purification  by  flash  chromatography
eluting  with  CH2Cl2/MeOH  (9:1)  in  58%  yield:  mp  300  °C
(dec);  1H NMR (200 MHz,  DMSO-d6)  δ  1.25 (t,  J  =  7.0  Hz,
3H, CH2CH3), 3.05-3.10 and 3.50-3.55 (m, each 4H, piperazine
CH2), 3.80 (bs, 4H, imidazoline CH2), 3.90 (s, 3H, CH3), 4.20
(q, J = 7.0 Hz, 2H, CH2CH3), 5.25 (bs, 2H, NH2), 7.00 (s, 1H,
H-8), 7.15 (d, J = 5.0 Hz, 1H, pyridine CH), 7.45 (s, 1H, H-5),
7.60-7.65  (m,  1H,  pyridine  CH),  8.30  (d,  J  =  5.0  Hz,  1H,
pyridine CH), 8.40 (s, 1H, H-2).
2.1.10. General Procedure for Basic Hydrolysis (Method C)
A suspension  of  selected  ethyl  ester  (0.3  mequiv)  in  4%
NaOH (5 mL) was refluxed until no starting material could be
detected by TLC (4-20 h). After cooling the reaction mixture
was acidified to pH = 4 with 2N HCl, obtaining a precipitate
which  was  filtered,  washed  with  water,  and  purified  as
described  below.
2.1.11. 6-Amino-7-{4-[4-(4,5-Dihydro-1h-Imidazol-2-Yl) Pyri-
din -2-Yl]Piperazin-1-Yl}-1-Methyl-4-Oxo-1,4-Dihydroquino-
line-3-Carboxylic Acid (3)
The title  compound was  obtained  starting  from 20  using
Method C (15 h) after crystallization from DMF in 32% yield:
mp > 300 °C; 1H NMR (400 MHz, DMSO-d6) δ 2.80-2.90 and
3.00-3.25  (m,  each  4H,  piperazine  CH2),  3.50  (bs,  4H,
imidazoline CH2), 3.90 (s, 3H, CH3), 5.00 (bs, 1H, NH), 5.50
(bs,  2H, NH2),  6.90 (s,  1H, H-8),  7.10-7.25 (m, 2H, pyridine
CH), 7.50 (s, 1H, H-5), 8.25 (d, J = 5.0 Hz, 1H, pyridine CH),
8.75 (s, 1H, H-2), 11.20 (COOH). Anal. calcd. for C23H25N7O3:
C 61.73, H 5.63, N 21.91, found: C 61.98, H 5.82, N 21.73.
2.1.12. General Procedure for the Cycloaracylation Reaction,
Step 1 (Method D)
A mixture  of  acrylate  (1.0  equiv)  and  appropriate  amine
(1.2  equiv)  in  a  mixture  of  Et2O/EtOH  (3:1),  was  stirred  at
room  temperature  until  no  starting  material  was  detected  by
TLC (30 min-2 h). The reaction mixture was then concentrated
in vacuo, yielding a residue which was used in the consecutive
step without further purification.
2.1.13.  Ethyl  2-(2,4-Dichloro-5-Nitrobenzoyl)-3-(Pyridin-2-
Ylmethylamino)Acrylate (22)
The title compound was obtained starting from 21 [30] and
(pyridin-2-ylmethyl)amine using Method D (2 h) in 78% yield:
mp 98-99 °C; 1H-NMR (200 MHz, CDCl3)  δ 1.00 (t,  J  = 7.1
Hz, 3H, CH2CH3), 4.00 (q, J = 7.1 Hz, 2H, CH2CH3), 4.75 (d, J
= 5.9 Hz, 2H, CH2), 7.15-7.25 (m, 2H, pyridine CH), 7.50 (s,
1H, H-3’), 7.70-7.80 (m, 2H, pyridine CH and H-6’), 8.30 (d, J
=  14.0  Hz,  1H,  vinyl  CH),  8.65-8.75  (m,  1H,  pyridine  CH),
11.40-11.50 (m, 1H, NH).
2.1.14.  Ethyl  3-[(3-Bromopropyl)Amino]-2-(2,4-Dichloro-5-
Nitrobenzoyl)Acrylate (23)
The title compound was obtained starting from 21 [30] and
(3-bromopropyl)amine using Method D (30 min) as keto-enolic
mixture  in  66%  yield:  mp  66-67  °C;  1H-NMR  (200,  MHz,
DMSO-d6)  δ  0.75  and  0.90  (t,  J  =  7.0  Hz,  0.75  and  2.25H,
CH2CH3),  2.10-2.25  (m,  2H,  CH2),  3.50-3.75  (m,  4H,  CH2),
3.90 (q, J = 7.0 Hz, 2H, CH2CH3), 4.20 (bs, 1H, NH), 8.10 (s,
2H,  H-3’  and  H-6’),  8.20-8.25  (m,  1H,  vinyl  CH),  9.75  (bs,
0.75H, OH), 10.90 (bs, 0.25H, NH).
2.1.15. Ethyl 2-(2,4-Dichloro-5-Nitrobenzoyl) -3-{[3-(Pyridin
-2 -Ylamino)Propyl]Amino}Prop-2-Enoate (24)
The title compound was obtained as an oil,  starting from
21  [30] and N-(pyridine-2-yl)propane-1,3-diamine [31] using
Method D (30 min) in 29% yield; 1H-NMR (200 MHz, CDCl3)
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δ  1.05  (t,  J  =  7.1  Hz,  3H,  CH2CH3),  1.90-2.00  (m,  2H,
CH2CH2CH2), 3.50-3.60 (m, 4H, CH2CH2CH2), 3.95-4.05 (q, J
= 7.1 Hz, 2H, CH2CH3), 4.50 (bs, 1H, NH) 6.35-6.45 (m, 1H,
pyridine CH), 6.60-6.70 (m, 1H, pyridine CH), 7.30-7.40 (m,
1H,  pyridine  CH),  7.55  (s,  1H,  H-3’),  8.75  (s,  1H,  H-6’),
8.20-8.30 (m, 2 H, vinyl CH and pyridine CH), 11.25 (bs, 1 H,
NH).
2.1.16.  General  Procedure  For  The  Cycloaracylation
Reaction, Step 2 (Method E)
A mixture of acrylate intermediate (1.0 equiv) and K2CO3
(3.0  equiv)  in  dry  DMF  was  heated  at  80°C  for  1  h.  After
cooling, the reaction mixture was poured into ice/water, giving
a precipitate that was filtered, washed with water and then with
Et2O.
2.1.17.  Ethyl  7-Chloro  -6-Nitro-4  -Oxo-1-  (Pyridin  -2-
Ylmethyl) -1,4- Dihydroquinoline- 3-Carboxylate (25)
The title  compound was  obtained  starting  from 22  using
Method E in 86% yield: mp 228-230 °C; 1H NMR (400 MHz,
CDCl3) δ 1.30 (t, J = 7.1 Hz, 3H, CH2CH3), 4.45 (q, J = 7.1 Hz,
2H,  CH2CH3),  5.40 (s,  2H,  CH2),  7.20-7.30 (m,  2H,  pyridine
CH),  7.55  (s,  1H,  H-8),  7.65-7.75  (m,  1H,  pyridine  CH),
8.50-8.60 (m, 2H, pyridine CH and H-2), 8.95 (s, 1H, H-5).
2.1.18. Ethyl 1-(3-Bromopropyl)-7-Chloro-6-Nitro-4-Oxo-1,4-
Dihydroquinoline-3-Carboxylate (26)
The title  compound was  obtained  starting  from 23  using
Method E in 88% yield: mp 180-181°C; 1H NMR (400 MHz,
DMSO-d6) δ 1.30 (t, J = 7.0 Hz, 3H, CH2CH3), 2.15-2.30 (m,
2H, CH2CH2CH2), 3.70 (t, J = 7,5 Hz, 2H, NCH2) 4.25 (q, J =
7.0 Hz, 2H, CH2CH3), 4.50-4.60 (m, 2H, CH2Br), 8.25 (s, 1H,
H-8), 8.75 (s, 1H, H-5), 8.80 (s, 1H, H-2).
2.1.19.  Ethyl  7-  Chloro-  6-Nitro-4-Oxo-1-  [3-(Pyridin-2-
Ylamino) Propyl]-1,4- Dihydroquinoline-3- Carboxylate (27)
The title  compound was  obtained  starting  from 24  using
Method E in 77% yield: mp 148-149 °C; 1H NMR (400 MHz,
CDCl3) δ 1.40 (t, J = 7.1 Hz, 3H, CH2CH3), 2.20-2.30 (m, 2H,
CH2CH2CH2)  3.50-3.60  (m,  2H,  NCH2),  4.30-4.45  (m,  4H,
CH2NH and CH2CH3), 4.60-4.70 (m, 1H, NH), 6.40-6.50 and
6.55-6.65 and 7.40-7.50 (m,  each 1H,  pyridine CH),  7.75 (s,
1H, H-8), 8.00-8.10 (m, 1H, pyridine CH), 8.60 (s, 1H, H-2),
9.00 (s, 1H, H-5).
2.1.20. Ethyl 6- Nitro -4-Oxo-1- (Pyridin-2-Ylmethyl) -7-(4-
(Pyridin2-yl)  Piperazin-1-yl])  -1,4-  Dihydroquinoline  -3-
Carboxylate  (28)
The title compound was obtained starting from 25 and 1-
(2-pyridinyl)piperazine  using  Method  A  (80°C,  2  h)  in  88%
yield: mp 181-183 °C; 1H NMR (400 MHz, CDCl3) δ 1.35 (t, J
= 7.0 Hz, 3H, CH2CH3), 3.05-3.15 and 3.55-3.65 (m, each 4H,
piperazine CH2), 4.45 (q, J = 7.0 Hz, 2H, CH2CH3), 5.35 (s, 2H,
CH2),  6.60-6.70  (m,  2H,  pyridine  CH),  6.90  (s,  1H,  H-8),
7.15-7.30  (m,  2H,  pyridine  CH),  7.40-7.50,  7.60-7.70,  and
8.15-8.25 (m, each 1H, pyridine CH), 8.60-8.65 (m, 2H, H-2
and pyridine CH), 8.80 (s, 1H, H-5).
2.1.21.  Ethyl  6-Nitro-4-Oxo-7-(4-(Pyridin2-yl)Piperazin-1-
yl])-1-[3-(4-(Pyridin2-yl)Piperazin-1-yl])Propyl]-1,4-
Dihydroquinoline-3-Carboxylate  (29)  And  Ethyl  1-(3-
Bromopropyl)-6-Nitro-4-Oxo-7-(4-(Pyridin2-yl)Piperazin-1-
yl])-1,4-Dihydroquinoline-3-Carboxylate (30)
The title compounds were obtained starting from 26 and 1-
(2-pyridinyl)piperazine  using  Method  A  (40°C,  72  h)  after
purification  by  flash  chromatography  eluting  with  CHCl3/
MeOH (from 100:0 to 80:20) in 53% yield (compound 29) and
23%  yield  (compound  30);  compound  29:  mp  89-91  °C;  1H
NMR (400 MHz, CDCl3) δ 1.40 (t, J = 7.0 Hz, 3H, CH2CH3),
2.05-2.10  and  2.40-2.45  (m,  each  2H,  CH2),  2.50-2.60,
3.25-3.35,  3.50-3.60  and  3.75-3.85  (m,  each  4H,  piperazine
CH2), 4.25-4.45 (m, 4H, CH2CH3 and CH2), 6.60-6.75 (m, 4H,
pyridine CH), 6.90 (s, 1H, H-8), 7.45-7.55 and 8.15-8.25 (m,
each 2H, pyridine CH), 8.60 (s,  1H, H-5), 8.80 (s,  1H, H-2);
compound 30: mp 209-210 °C; 1H NMR (400 MHz, CDCl3) δ
1.40  (t,  J  =  7.0  Hz,  3H,  CH2CH3),  2.30-2.50  (m,  2H,  CH2),
3.25-3.40  (m,  4H,  piperazine  CH2),  3.60-3.80  (m,  6H,
piperazine CH2 and CH2), 4.30-4.50 (m, 4H, CH2CH3 and CH2),
6.60-6.75 (m, 2H, pyridine CH), 7.00 (s, 1H, H-8), 7.50 (t, J =
6.4  Hz,  1H,  pyridine  CH),  8.15-8.25  (m,  1H,  pyridine  CH),
8.40 (s, 1H, H-5), 8.80 (s, 1H, H-2).
2.1.22.  Ethyl  6-  Nitro  -4-Oxo-1-  [3-(Pyridin-2-Ylamino)
Propyl]-7-  (4-(Pyridin2-yl)  Piperazin-1-yl])  -1,4-  Dihydro-
quinoline  -3-  Carboxylate  (31)
The title compound was obtained starting from 27 and 1-
(2-pyridinyl)piperazine using Method A (80 °C, 3 h), in 100%
yield: mp 124-125 °C; 1H NMR (400 MHz, CDCl3) δ 1.40 (t, J
= 7.1 Hz, 3H, CH2CH3), 2.20-2.30 (m, 2H, NCH2CH2CH2NH),
3.10-3.20  (m,  4H,  piperazine  CH2),  3.50-3.60  (m,  2H,
NCH2CH2CH2NH),  3.65-3.75  (m,  4H,  piperazine  CH2),
4.25-4.40 (m, 4H, NCH2CH2CH2NH and CH2CH3), 4.75-4.85
(m, 1H, NH), 6.35-6.45 (m, 1H, pyridine CH), 6.55-6.70 (m,
3H,  pyridine  CH),  6.80  (s,  1H,  H-8),  7.30-7.40,  7.45-7.55,
8.05-8.15, and 8.15-8.25 (m, each 1H, pyridine CH), 8.45 (s,
1H, H-5), 8.85 (s, 1H, H-2).
2.1.23.  Ethyl  6-Nitro-4-Oxo-1-(3-(Piperazin-1-Yl)Propyl)-7-
(4-(Pyridin2-yl)Piperazin-1-yl])-1,4-Dihydroquinoline-3-
Carboxylate (32)
Piperazine (0.08 g, 9.39 mmol) and DIPEA (0.12 g, 9.38
mmol) were added to a solution of 30 (0.13 g, 2.34 mmol) in
dry DMF (5 mL), and the mixture was stirred at 80 °C for 48 h.
After cooling, the reaction mixture was evaporated to dryness
and the residue was purified by flash chromatography eluting
with CHCl3/MeOH/NH4OH (from 90:10:0 to 79:20:1), to give
32  (0.08  g,  63%):  mp  186-189  °C;  1H  NMR  (400  MHz,
DMSO-d6) δ 1.15 (t, J = 7.0 Hz, 3H, CH2CH3), 1.90-2.00 and
2.10-2.15  (m,  each  2H,  CH2),  2.20-2.30,  2.90-3.0,  3.10-3.20
and 3.70-3.80 (m, each 4H, piperazine CH2), 4.10 (q, J = 7.0
Hz, 2H, CH2CH3), 4.20-4.30 (m, 2H, CH2), 6.70 (t, J = 6.5 Hz,
1H, pyridine CH), 6.90 (d, J = 9.3 Hz, 1H, pyridine CH), 7.10
(s, 1H, H-8), 7.60 (t, J = 6.5 Hz, 1H, pyridine CH), 8.10-8.20
(m, 1H, pyridine CH), 8.60 (s, 1H, H-5), 8.70 (s, 1H, H-2).
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2.1.24.  Ethyl  6-Amino-4-Oxo-1-(Pyridin-2-Ylmethyl)-7-(4-
(Pyridin2-yl)Piperazin-1-yl])-1,4-Dihydroquinoline-3-
Carboxylate (33)
The title  compound was  obtained  starting  from 28  using
Method B (45 min)  in  34% yield:  mp 268-270 °C;  1H NMR
(400  MHz,  DMSO-d6)  δ  1.30  (t,  J  =  7.0  Hz,  3H,  CH2CH3),
2.75-2.85 and 3.60-3.70 (m, each 4H, piperazine CH2), 4.25 (q,
J  =  7.0  Hz,  2H,  CH2CH3),  5.20  (bs,  2H,  NH2),  5.70  (s,  2H,
CH2), 6.70 (t, J  = 5.0 Hz, 1H, pyridine CH), 6.85 (d, J  = 8.5
Hz, 1H, pyridine CH), 7.00 (s, 1H, H-8), 7.30 (t, J = 5.2 Hz,
1H,  pyridine  CH),  7.35-7.45  (m,  2H,  H-5  and  pyridine  CH),
7.60 and 7.80 (t, J = 7.0 Hz, each 1H, pyridine CH), 8.20 and
8.45 (d, J = 3.7 Hz, each 1H, pyridine CH), 8.75 (s, 1H, H-2).
2.1.25.  Ethyl  6-Amino-4-Oxo-7-(4-(Pyridin2-yl)Piperazin-1-
yl])-1-[3-(4-(Pyridin2-yl)Piperazin-1-yl])Propyl]-1,4-
Dihydroquinoline-3-Carboxylate (34)
The title  compound was  obtained  starting  from 29  using
Method B (1 h) in 88% yield: mp 233-234 °C; 1H NMR (400
MHz, DMSO-d6) δ 1.25 (t, J = 7.1 Hz, 3H, CH2CH3), 1.90-2.00
(m,  2H,  CH2),  2.20-2.40  (m,  6H,  CH2  and  piperazine  CH2),
3.10-3.20  and  3.40-3.50  (m,  each  4H,  piperazine  CH2),
3.70-3.75  (m,  4H,  piperazine  CH2),  4.20  (q,  J  =  7.1  Hz,  2H,
CH2CH3),  4.45-4.50  (m,  2H,  CH2),  5.25  (bs,  2H,  NH2),
6.65-6.70 (m, 2H, pyridine CH), 6.80 and 6.90 (d, J = 5.0 Hz,
each 1H, pyridine CH), 7.15 (s,  1H, H-8),  7.45-7.55 (m, 3H,
H-5 and pyridine CH), 8.10-8.20 (m, 2H, pyridine CH), 8.50 (s,
1H, H-2).
2.1.26.  Ethyl  6  -Amino  -4-  Oxo-1-  [3-(Pyridin-2-Ylamino)
Propyl]  -7-  (4-(Pyridin2-yl)  Piperazin-1-yl])  -1,4-  Dihydro-
quinoline-3- Carboxylate (35)
The title  compound was  obtained  starting  from 31  using
Method B (15 min)  in  46% yield:  mp 244-245 °C;  1H NMR
(400  MHz,  DMSO-d6)  δ  1.25  (t,  J  =  7.1  Hz,  3H,  CH2CH3),
1.95-2.05  (m,  2H,  NCH2CH2CH2NH),  2.80-2.95  (m,  4H,
piperazine  CH2),  3.20-3.30  (m,  2H,  NCH2CH2CH2NH),
4.60-4.75  (m,  4H,  piperazine  CH2),  4.20  (q,  J  =  7.1  Hz,  2H,
CH2CH3),  4.25-4.35 (m,  2H,  NCH2CH2CH2NH),  5.25 (s,  2H,
NH2), 6.40-6.50 and 6.65-6.75 (m, each 2H, pyridine CH), 7.00
(s,  1H,  H-8),  7.25-7.35  (m,  1H,  pyridine  CH),  7.50-7.60  (m,
2H, pyridine CH and H-5), 7.85-7.95 and 8.10-8.20 (m, each
1H, pyridine CH), 8.50 (s, 1H, H-2).
2.1.27. Ethyl 6-Amino-4-Oxo-1-(3-(Piperazin-1-Yl)Propyl)-7-
(4-(Pyridin2-yl)Piperazin-1-yl])-1,4-Dihydroquinoline-3-
Carboxylate (36)
The title  compound was  obtained  starting  from 32  using
Method B (40 min)  in  88% yield:  mp 256-257 °C;  1H NMR
(200 MHz, methanol-d4) δ 1.35 (t, J = 7.0 Hz, 3H, CH2CH3),
2.05-2.10 (m, 2H, CH2), 2.40-2.50 (m, 6H, CH2 and piperazine
CH2),  2.90-3.00,  3.20-3.30,  and  3.70-3.80  (m,  each  4H,
piperazine CH2), 4.35 (q, J = 7.0 Hz, 2H, CH2CH3), 4.60-4.65
(m, 2H, CH2), 6.70 (t, J = 6.5 Hz, 1H, pyridine CH), 6.90 (d, J
= 9.3 Hz, 1H, pyridine CH), 7.20 (s, 1H, H-8), 7.60 (t, J = 6.5
Hz,  1H,  pyridine  CH),  7.65  (s,  1H,  H-5),  8.10-8.20  (m,  1H,
pyridine CH), 8.70 (s, 1H, H-2).
2.1.28.  6-  Amino-4-Oxo-1-  (Pyridin-2-Ylmethyl)  -7-(4-
(Pyridin2-yl)  Piperazin-1-yl])  -1,4-  Dihydroquinoline-3-
Carboxylic  Acid  (4)
The title  compound was  obtained  starting  from 33  using
Method C (20 h) after purification by treatment with Et2O in
64% yield: mp 287-288 °C; 1H NMR (400 MHz, DMSO-d6) δ
2.85-2.95  and  3.65-3.75  (m,  each  4H,  piperazine  CH2),  5.45
(bs,  2H,  NH2),  5.90  (s,  2H,  CH2),  6.65  (t,  J  =  5.7  Hz,  1H,
pyridine CH), 6.95 (d, J = 8.6 Hz, 1H, pyridine CH), 7.20 (s,
1H, H-8), 7.25-7.35 (m, 1H, pyridine CH), 7.50-7.60 (m, 3H,
H-5 and pyridine CH), 7.80 (t, J = 7.1 Hz, 1H, pyridine CH),
8.20 and 8.50 (d, J = 3.3 Hz, each 1H, pyridine CH), 9.00 (s,
1H, H-2), 15.90 (s, 1H, COOH); 13C NMR (101 MHz, DMSO-
d6)  δ  45.08 (2C),  49.90 (2C),  58.54,  106.46,  106.88,  107.66,
108.38,  113.67,  122.78,  122.85,  123.78,  132.67,  137.85,
138.10,  142.33,  145.67,  147.55,  148.08,  150.01,  155.17,
159.43, 167.47, 176.88. Anal. calcd. for C25H24N6O3: C 65.78,
H 5.30, N 18.41, found: C 70.03, H 5.32, N 18.48.
2.1.29.  6-Amino-4-Oxo-7-(4-(Pyridin2-yl)Piperazin-1-yl])-1-
[3-(4-(Pyridin2-yl)Piperazin-1-yl])Propyl]-1,4-
Dihydroquinoline-3-Carboxylic Acid (6)
The title  compound was  obtained  starting  from 34  using
Method C (6 h) after purification by crystallization from DMF
in 20% yield: mp > 300 °C; 1H NMR (400 MHz, DMSO-d6) δ
2.15-2.25 and 3.0-3.15 (m, each 2H, CH2), 3.25-3.70 (m, 10H,
piperazine CH2), 3.75-4.00 (m, 4H, piperazine CH2), 4.25-4.45
and 4.65-4.80 (m, each 2H, piperazine CH2 and CH2), 5.50 (bs,
2H, NH2), 6.75 and 6.95 (t, J = 6.4 Hz, each 1H, pyridine CH),
7.10 (d, J = 9.0 Hz, 1H, pyridine CH), 7.30 (s, 1H, H-8), 7.40
(d, J = 9.0 Hz, 1H, pyridine CH), 7.60 (s, 1H, H-5), 7.75 and
7.95 (t, J = 6.4 Hz, each 1H, pyridine CH), 8.05-8.15 (m, 2H,
pyridine CH),  8.80 (s,  1H,  H-2),  11.60 (bs,  1H,  COOH);  13C
NMR (101 MHz, DMSO-d6) δ 23.52, 42.75, 46.51 (2C), 49.42
(2C),  50.68  (2C),  51.34,  53.00  (2C),  106.67,  107.44  (2C),
108.13,  113.39,  114.49  (2C),  123.15,  132.23,  135.9,  137.9,
142.31, 145.50, 146.31 (2C), 151.06, 152.93, 153.60, 167.33,
176.74. Anal. calcd. for C31H36N8O3: C 65.47, H 6.38, N 19.70,
found: C 65.40, H 6.70, N 19.55.
2.1.30.  6-Amino-4-Oxo-1-[3-(Pyridin-2-Ylamino)Propyl]-7-
(4-(Pyridin2-yl)Piperazin-1-yl])-1,4-Dihydroquinoline-3-
Carboxylic Acid Hydrochloride (7)
The title  compound was  obtained  starting  from 35  using
Method  C  (6  h)  after  purification  by  treatment  with  Et2O in
91% yield: mp 290 °C (c); 1H NMR (400 MHz, DMSO-d6) δ
2.00-2.10 (m, 2H, CH2CH2CH2), 3.10-3.20 (m, 4H, piperazine
CH2), 3.40-3.50 (m, 2H, NCH2), 3.90-4.00 (m, 4H, piperazine
CH2), 4.65-4.75 (m, 2H, CH2NH), 6.75-6.85 and 6.90-7.00 (m,
each  1H,  pyridine  CH),  7.10-7.20  (m,  1H,  pyridine  CH),
7.35-7.45  (m,  2H,  H-8  and  pyridine  CH),  7.60  (s,  1H,  H-5),
7.80-8.00  (m,  3H,  pyridine  CH),  8.10-8.20  (m,  1H,  pyridine
CH), 8.75 (s, 1H, H-2), 9.35 (s, 1H, NH); 13C NMR (101 MHz,
DMSO-d6)  δ  28.42,  39.45,  46.81  (2C),  49.62  (2C),  51.63,
106.79,  108.62,  112.39  (2C),  112.98,  113.36  (2C),  123.10,
133.11, 135.91, 137.90, 140.91, 144.44 (2C), 146.00, 146.55,
152.45, 152.96, 167.20, 176.64. Anal. calcd. for C27H30ClN7O3:
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C 60.50, H 5.64, N 18.29, found: C 60.62, H 5.77, N 18.33.
2.1.31.  6-Amino-4-Oxo-1-(3-(Piperazin-1-Yl)Propyl)-7-(4-
(Pyridin2-yl)Piperazin-1-yl])-1,4-Dihydroquinoline-3-
Carboxylic Acid (8)
The title  compound was  obtained  starting  from 36  using
Method C (4 h) after purification by crystallization from DMF
in 60% yield: mp > 300 °C; 1H NMR (400 MHz, DMSO-d6) δ
2.00-2.20 (m, 2H, CH2), 3.00-3.25 and 3.30-3.55 (m, each 8H,
piperazine CH2), 3.90-4.00 and 4.50-4.60 (m, each 2H, CH2),
6.90 (t, J = 6.5 Hz, 1H, pyridine CH), 7.20 (s, 1H, H-8), 7.50
(d, J = 9.1 Hz, 1H, pyridine CH), 7.70 (s, 1H, H-5), 7.90-8.00
(m, 2H, pyridine CH), 8.70 (s, 1H, H-2); 13C NMR (101 MHz,
DMSO-d6) δ 23.48, 42.69, 45.32 (2C), 56.12 (2C), 50.73 (2C),
51.69,  53.25  (2C),  106.18,  107.35,  108.23,  113.45,  114.61,
123.38,  132.91,  136.12,  142.75,  145.56,  146.42,  151.18,
153.06, 167.45, 176.88. Anal. calcd. for C26H33N7O3: C 63.52,
H 6.77, N 19.95, found: C 63.79, H 7.02, N 20.13.
2.1.32.  Ethyl  7-  Chloro-4-Oxo-1-  [2-(4-(Pyridin2-yl)  Pipe-
razin-1-yl]) Ethyl] -1,4-Dihydro-1,8- Naphthyridine-3- Carbo-
xylate (40)
The title compound was obtained starting from 37 [32] and
[2-(4-(Pyridin2-yl)Piperazin-1-yl])ethyl]amine [33] using Met-
hod D (2 h) to give intermediate 38, followed by Method E in
56%  overall  yield:  mp  123-124°  C;  1H  NMR  (400  MHz,
DMSO-d6) δ 1.30 (t, J = 7.0 Hz, 3H, CH2CH3), 2.45-2.55 (m,
4H, piperazine CH2), 2.75 (t, J = 6.7 Hz, 2H, CH2), 3.40-3.50
(m,  4H,  piperazine CH2),  4.20 (q,  J  =  7.0  Hz,  2H,  CH2CH3),
4.60 (t, J = 6.7 Hz, 2H, CH2), 6.60-6.65 (m, 1H, pyridine CH),
6.80  (d,  J  =  8.7  Hz,  1H,  pyridine  CH),  7.50-7.60  (m,  1H,
pyridine CH), 7.65 (d, J = 8.3 Hz, 1H, H-6), 8.10-8.15 (m, 1H,
pyridine CH), 8.60 (d, J = 8.3 Hz, 1H, H-5), 8.85 (s, 1H, H-2).
2.1.33.  Ethyl  7-  Chloro-4-Oxo-1-  [3-(4-(Pyridin2-yl)  Pipe-
razin-1-yl])  Propyl]-1,4-  Dihydro-1,8-  Naphthyridine-3-
Carboxylate  (41)
The title compound was obtained starting from 37 [32] and
[3-(4-(pyridin-2-yl)piperazin-1-yl)propyl]amine  [33]  using
Method D (2 h) to give intermediate 39, followed by Method E
in  59%  overall  yield:  mp  124-125  °C;  1H  NMR  (400  MHz,
DMSO-d6) δ 1.30 (t, J = 7.0 Hz, 3H, CH2CH3), 2.00 (t, J = 6.7
Hz,  2H,  NCH2CH2),  2.40-2.50  (m,  6H,  CH2  and  piperazine
CH2) 3.40-3.50 (m, 4H, piperazine CH2), 4.25 (q, J = 7.0 Hz,
2H, CH2CH3),  4.50 (t,  J  = 6.7 Hz, 2H, NCH2CH2),  6.60-6.65
(m, 1H, pyridine CH), 6.80 (d, J = 8.7 Hz, 1H, pyridine CH),
7.50-7.60 (m, 1H, pyridine CH), 7.65 (d, J = 8.3 Hz, 1H, H-6),
8.10-8.15 (m, 1H, pyridine CH), 8.55 (d, J = 8.3 Hz, 1H, H-5),
8.90 (s, 1H, H-2).
2.1.34.  Ethyl  7-[4-(1,3-Benzothiazol-2-Yl)Piperazin-1-Yl]-4-
Oxo-1-[2-(4-(Pyridin2-yl)Piperazin-1-yl])Ethyl]-1,4-
Dihydro-1,8-Naphthyridine-3-Carboxylate (42)
The title compound was obtained starting from 40 and 1-
(1,3-benzothiazol-2-yl)piperazine [34] using Method A (80 °C,
24  h).  After  cooling  the  reaction  mixture  was  poured  into
ice/water and extracted with CH2Cl2. The organic layers were
evaporated to dryness affording an oil, which was tritured with
Et2O, giving  a  solid  which  was  filtered,  to  afford  42  in  68%
yield: mp 124-125 °C; 1H NMR (400 MHz, DMSO-d6) δ 1.25
(t,  J  =  7.0  Hz,  3H,  CH2CH3),  2.50-2.60  (m,  4H,  piperazine
CH2), 2.75 (t, J = 6.7 Hz, 2H, CH2), 3.40-3.50, 3.65-3.75, and
3.80-3.90 (m, each 4H, piperazine CH2), 4.20 (q, J = 7.0 Hz,
2H, CH2CH3), 4.75 (t, J = 6.7 Hz, 2H, CH2), 6.60-6.65 (m, 1H,
pyridine CH), 6.80 (d, J = 8.7 Hz, 1H, pyridine CH), 7.00-7.10
(m, 2H, H-6 and benzothiazole CH), 7.25 (t, J = 7.4 Hz, 1H,
benzothiazole  CH),  7.40-7.50  (m,  2H,  pyridine  CH  and
benzothiazole  CH),  7.75  (d,  J  =  7.9  Hz,  1H,  benzothiazole
CH),  8.05-8.10  (m,  1H,  pyridine  CH),  8.20  (d,  J  =  8.8  Hz,
H-5), 8.60 (s, 1H, H-2).
2.1.35.  Ethyl  7-[4-(1,3-Benzothiazol-2-Yl)Piperazin-1-Yl]-4-
Oxo-1-[3-(4-(Pyridin2-yl)Piperazin-1-yl])Propyl]-1,4-
Dihydro-1,8-Naphthyridine-3-Carboxylate (43)
The title compound was obtained starting from 41 and 1-
(1,3-benzothiazol-2-yl)piperazine [34] using Method A (80 °C,
24  h)  in  63%  yield:  mp  140-141  °C;  1H  NMR  (400  MHz,
DMSO- d6) δ 1.30 (t, J = 7.0 Hz, 3H, CH2CH3), 2.00 (t, J = 6.7
Hz,  2H,  NCH2CH2),  2.40-2.50  (m,  6H,  CH2  and  piperazine
CH2),  3.40-3.50,  3.65-3.75  and  3.85-3.95  (m,  each  4H,
piperazine CH2), 4.20 (q, J = 7.0 Hz, 2H, CH2CH3), 4.40 (t, J =
6.7 Hz, 2H, NCH2CH2), 6.60-6.65 (m, 1H, pyridine CH), 6.80
(d, J = 8.7 Hz, 1H, pyridine CH), 7.00-7.10 (m, 2H, H-6 and
benzothiazole CH), 7.25 (t, J = 7.4 Hz, 1H, benzothiazole CH),
7.40-7.50 (m, 2H, pyridine CH and benzothiazole CH), 7.75 (d,
J = 7.9 Hz, 1H, benzothiazole CH), 8.05-8.10 (m, 1H, pyridine
CH), 8.20 (d, J = 8.8 Hz, H-5), 8.60 (s, 1H, H-2).
2.1.36.  7-[4-(1,3-Benzothiazol-2-Yl)Piperazin-1-Yl]-4-Oxo-1-
[2-(4-(Pyridin-2-Yl)Piperazin-1-Yl)Ethyl]-1,4-Dihydro-1,8-
Naphthyridine-3-Carboxylic Acid (11)
The title  compound was  obtained  starting  from 42  using
Method C (2 h) after purification by crystallization from DMF
in 41% yield: mp 294-295 °C (dec.) °C; 1H NMR (400 MHz,
DMSO-d6) δ 2.50-2.60 (m, 4H, piperazine CH2), 2.75 (t, J = 6.7
Hz, 2H, CH2), 3.30-3.40, 3.65-3.75, and 3.90-4.00 (m, each 4H,
piperazine CH2), 4.65 (t, J = 6.7 Hz, 2H, CH2), 6.60-6.65 (m,
1H, pyridine CH), 6.80 (d, J = 8.7 Hz, 1H, pyridine CH), 7.05
(t, J = 7.7 Hz, 1H, benzothiazole CH), 7.20-7.30 (m, 2H, H-6
and  benzothiazole  CH),  7.40-7.50  (m,  2H,  pyridine  CH  and
benzothiazole  CH),  7.75  (d,  J  =  7.9  Hz,  1H,  benzothiazole
CH),  8.05-8.10  (m,  1H,  pyridine  CH),  8.30  (d,  J  =  8.8  Hz,
H-5), 8.80 (s, 1H, H-2), 15.50 (s, 1H, COOH); 13C NMR (101
MHz, DMSO-d6) δ 44.21 (2C), 45.27, 47.86 (4C), 52.82 (2C),
56.23, 107.61, 107.81, 108.41, 111.50, 113.54, 119.20, 121.75,
121.88,  126.53,  130.90,  136.42,  137.98,  147.99,  149.62,
150.01, 152.80, 159.29, 159.46, 166.63, 168.47, 177.04. Anal.
calcd.  for  C31H32N8O3S:  C  62.40,  H  5.41,  N  18.78,  found:  C
62.25, H 5.70, N 18.65.
2.1.37.  7-[4-(1,3-Benzothiazol-2-Yl)Piperazin-1-Yl]-4-Oxo-1-
[3-(4-(Pyridin-2-Yl)Piperazin-1-Yl)Propyl]-1,4-Dihydro-1,8-
Naphthyridine-3-Carboxylic Acid (12)
The title  compound was  obtained  starting  from 43  using
Method C (2 h) after purification by crystallization from DMF
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in  16%  yield:  mp  256-257  °C  (dec);  1H  NMR  (400  MHz,
DMSO-d6) δ 2.00 (t, J = 6.7 Hz, 2H, CH2), 2.25-2.35 (m, 6H,
CH2 and piperazine CH2), 3.25-3.35, 3.65-3.75 and 3.95-4.00
(m, each 4H, piperazine CH2), 4.50 (t, J  = 6.7 Hz, 2H, CH2),
6.60-6.65  (m,  1H,  pyridine  CH),  6.75  (d,  J  =  8.7  Hz,  1H,
pyridine  CH),  7.05  (t,  J  =  7.7  Hz,  1H,  benzothiazole  CH),
7.20-7.30 (m, 2H, H-6 and benzothiazole CH), 7.40-7.50 (m,
2H, pyridine CH and benzothiazole CH), 7.75 (d, J = 7.9 Hz,
1H, benzothiazole CH), 8.05-8.10 (m, 1H, pyridine CH), 8.30
(d, J = 8.8 Hz, H-5), 9.00 (s, 1H, H-2), 15.50 (s, 1H, COOH);
13C NMR (101  MHz,  DMSO-d6)  δ  23.62,  42.93,  46.48  (2C),
48.31  (2C),  49.16  (2C),  51.42,  52.87  (2C),  107.53,  108.16,
108.43, 111.62, 113.48, 119.1, 122.15, 122.88, 126.41, 131.10,
136.72,  138.22,  148.34,  150.21,  150.34,  152.98,  159.75,
159.88, 166.89, 169.17, 177.25. Anal. calcd. for C32H34N8O3S:
C 62.93, H 5.61, N 18.35, found: C 62.98, H 5.60, N 18.35. .
2.2. Biology
2.2.1. In vitro Anti-HIV Assays
The  evaluation  of  the  antiviral  activity  of  the  target
compounds  against  HIV-1  strain  IIIB  in  MT-4  cells   was
 performed using  the MTT  assay  as  previously  described
 [35, 36]. Mock-infected cells were used to assess the cytotoxic
effects of the test compounds.
2.2.2. Fluorescence Quenching Assay (FQA)
The effect of tested quinolones on the Tat-TAR complex
was evaluated using an FQA, a FRET-based competition assay,
as  previously  described  [23],  using  the  Tat-derived  peptide
labelled with the donor fluorescein at its N terminus and the 29
nt  wtTAR  labeled  at  its  3’-end  with  a  dabcyl  moiety
(quencher).
3. RESULTS AND DISCUSSION
3.1. Chemistry
The introduction of the guanidine group at C-6 position in
the quinolone derivative 1 was accomplished by reacting WM5
[20] with N,N′-di-(tert-butoxycarbonyl)thiourea in the presence
of  HgCl2  followed  by  Boc  deprotection  of  intermediate  13
under acid conditions Scheme (1).
The  synthesis  of  the  C-7  4-carbamimidoylpiperazine
derivative 2 started by reacting derivative 14 [28] with methyl
imidothiocarbamate  sulfate  to  give  intermediate  15,  which,
after reduction of the nitro group accomplished with FeSO4 and
NH4OH followed  by  acid  hydrolysis  of  the  ethyl  ester  inter-
mediate, led to the target compound 2 Scheme (2).
The  C-7  imidazolinpyridinpiperazine  derivative  3  was
synthesized,  as  outlined  in  Scheme  (3),  by  reacting  inter-
mediate 17 [20] with the 1- [4- (4,5-dihydro-1H-imidazol-2-yl)
pyridin-2-yl] piperazine 18 in DMF, affording intermediate 19.
Nitro  derivative  19  was  then  catalytically  reduced  to  amino
derivative 20 and finally hydrolysed under basic conditions to
give  the  target  compound  3.  The  required  building  block  18
was in turn prepared through the reaction of nitrile derivative
16 [29] with ethylenediamine in presence of p-toluenesulfonic
acid.
The synthesis of quinolone derivatives 4 and 6-8 Scheme
(4)  was  accomplished  through  a  cycloaracylation  procedure.
Thus, acrylate 21  [30] was reacted with (pyridin-2-ylmethyl)
amine,  (3-bromopropyl)  amine,  and  N-(pyridin-2-yl)  pro-
pane-1,3-diamine in Et2O/EtOH mixture at room temperature
to give intermediates 22-24, which by treatment with K2CO3 in
dry DMF at 80 °C afforded synthons 25-27. These derivatives
were  then  subjected  to  nucleophilic  reaction  with  1-(2-
pyridinyl) piperazine in dry DMF, to give intermediates 28-31.
In the case of compound 26, the nucleophilic reaction led to the
mixture  of  the  di-substituted  29  and  mono-substituted  30,
which were easily isolated by chromatographical purification.
Intermediate 30 was then functionalized at the N-1 position by
reaction  with  piperazine  in  presence  of  DIPEA  in  dry  DMF
affording derivative  32.  Then,  the  6-nitro-derivatives  28,  29,
31,  and  32  were  catalytically  reduced  to  give  6-amino-deri-
vatives 33-36.  Finally,  the target  compounds 4  and 6-8  were
obtained  by  saponification  of  the  corresponding  ethyl  esters
33-36.
By  following  an  analogous  synthetic  route,  1,8-naph-
thyridone derivatives 11 and 12 were prepared as presented in
Scheme (5). Thus, the reaction of acrylate 37 [32] with [2-(4-
(pyridin-2-yl)piperazin-1-yl)ethyl]amine  [33]  and  [3-(4-
(pyridin-2-yl)piperazin-1-yl)propyl]amine [33] in Et2 O/ EtOH
mixture  at  room  temperature  gave  intermediates  38  and  39,
which by treatment with K2CO3 in dry DMF at 80 °C, afforded
synthons 40 and 41, respectively. The nucleophilic reaction of
naphthyridone  derivatives  40  and  41  with  1-  (1,3-  ben-
zothiazol-2-yl) piperazine [34] led to intermediates 42 and 43.
Finally,  the  target  compounds  11  and  12  were  obtained  by
saponification of the corresponding ethyl esters 42 and 43.
Scheme 1. Reagents and conditions: (i) N,N′-di-(tert-butoxycarbonyl)thiourea, HgCl2, Et3N, dry DMF, rt; (ii) HCl g, CHCl3, EtOH, rt.
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Scheme 2. Reagents and conditions: (i) methyl imidothiocarbamate sulfate, dry DMSO, 120 °C; (ii) FeSO4.7H2O, NH4OH, H2O, rt; (iii) 6N HCl,
EtOH, reflux.
Scheme 3. Reagents and conditions: (i) ethylenediamine, p-toluenesulfonic acid, reflux; (ii) dry DMF, K2CO3, 80 °C; (iii) H2, Raney Ni, DMF rt; (iv)
4% NaOH, reflux.
Scheme 4.  Reagents  and conditions:  (i)  (pyridin-2-ylmethyl)amine,  (3-bromopropyl)amine,  or  N-(pyridin-2-yl)propane-1,3-diamine,  Et2O/EtOH
(3:1)rt; (ii) K2CO3, dry DMF rt, 80°C; (iii) 1-(2-pyridinyl)piperazine, dry DMF, K2CO3, 80°C; (iv) piperazine, DIPEA, dry DMF, 80°C; (v) H2, Raney
Ni, DMF; (vi) 4% NaOH, reflux.
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Scheme 5. Reagents and conditions: (i) [2-(4-(pyridin-2-yl)piperazin-1-yl)ethyl]amine, [3-(4-(pyridin-2-yl)piperazin-1-yl)propyl]amine, Et2O/EtOH
(3:1), rt; (ii) K2CO3, dry DMF, 80°C; (iii) 1-(1,3-benzothiazol-2-yl)piperazine, K2CO3, dry DMF, 80°C; (iv) H2, Raney Ni, DMF rt; (v) 4% NaOH,
reflux.
Table 1. Anti-HIV-1 activity and cytotoxicity of quinolones in MT-4 cells and inhibition of Tat-TAR complex formation.
Compd
EC50 (µM)
a,c
HIV-1 (IIIB)
CC50 (µM)
b,c SId Ki Tat-TAR (µM)e
1 >296 >296 1 N.T. f
2 >363 363 1 N.T.
3 >34.9 34.9 ± 1.43 <1 N.T.
4 >19.8 19.8 ± 5.02 <1 N.T.
5g 5.05 ± 0.41 20.9 ± 3.93 4 1.15 ± 0.55
6 1.21 ± 0.08 5.92 ± 2.19 5 0.91 ± 0.27
7 ≥3.42 3.94 ± 0.62 ≤1 2.18 ± 0.40
8 70.8 ± 0.71 >254 >4 N.T.
9g 1.16 ± 0.18 3.97 ± 0.70 3 N.D.h
10g ≥0.18 3.34 ± 1.47 ≤18 1.72 ± 0.22
11 3.37 ± 1.62 11.65 ± 1.17 3.5 N.D.
12 ≥0.67 10.70± 7.76 ≤16 N.D.
WM5i 0.15 ± 0.05 2.21 ± 1.05 15 2.22 ± 0.66
a EC50: concentration of compound required to achieve 50% protection of MT-4 cells from HIV-1 induced cytopathogenicity, as determined by the MTT method. 
b CC50:
concentration of compound that reduces the viability of mock-infected cells by 50%, as determined by the MTT method. c All data represent mean values ± standard
deviations for three separate experiments. d SI: ratio of CC50/EC50. 
e Ki from FQA experiments performed with 10 aa FAM–Tat peptide in Tris 10 mM, pH 7.5, Mg(ClO4)2 1
mM, NaCl 20 mM (TNMg), 0.01% Triton X-100. f N.T.: not tested. g Reference [25]. h N.D.: not determined due to solubility issue. i Reference [20].
3.2. Biological Evaluation
The newly synthesized compounds were initially evaluated
for anti-HIV-1 (IIIB) activity in MT-4 cells, determining their
cytotoxicity in parallel  Table 1.  WM5  [20] was evaluated in
the same cell lines for comparative purposes.
From the results, it emerged that the introduction of a C-6
guanidine group (compound 1) as well as an amidine moiety
and  a  4-imidazolinpyridine  ring  at  the  C-7  position  (com-
pounds 2 and 3) was completely detrimental in the inhibition of
HIV replication. However, the low cytotoxicity showed by the
compounds could suggest their inability to enter the cells.
The  introduction  of  a  2-pyridinylmethyl  moiety  at  N-1
position  (compound  4)  did  not  produce  an  active  derivative
(EC50 > 19.8 µM). Conversely, the presence of a (pyridin-2-yl)
piperazine spaced by an ethylene or propylene unit permitted to
restore the anti-HIV-1 activity in compounds 5 and 6 (EC50 =
5.05 and 1.21 µM, respectively) at no cytotoxic concentrations.
By alternatively deleting the piperazine or pyridine ring in
compound  6,  no  activity  at  subcytotoxic  concentrations  was
observed for compound 7, while only a weak inhibitory activity
was conserved by compound 8. More interesting results were
achieved when protonable side chains were inserted at the N-1
position  of  the  1,8-naphthyridone  scaffold.  In  particular,  the
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introduction  of  the  (pyridin-2-yl)piperazine  spaced  by  an
ethylene  or  propylene  unit  gave  compounds  11  and  12,  both
endowed with good anti-HIV-1 activity (EC50 = 3.37 and ≥0.67
µM) coupled with SI values of 3.5 and ≤16, respectively. The
deletion of the piperazine ring, as in compound 9 and 10, also
in this case permitted to maintain anti-HIV-1 (EC50 = 1.16 and
≥0.18 µM, SI = 3 and ≤18, respectively),  with compound 10
that emerged as the most potent of the series.
In  order  to  investigate  the  ability  of  active  anti-HIV-1
compounds  (derivative  5-7  and  9-12)  to  interfere  with  the
formation of the Tat-TAR complex, they were evaluated in a
FQA using a truncated Tat  peptide.  Unfortunately,  solubility
issues did not allow the evaluation of compounds 9, 11 and 12.
Derivatives 5, 6, and 10 appeared to be able to inhibit the Tat-
TAR  complex  formation,  all  presenting  Ki  values  even
improved as compared to the values obtained with WM5 Table
1.  In  particular,  enhancing  the  distance  of  the  pyridine  ring
from the  quinolone  nucleus,  the  ability  of  the  compounds  to
inhibit the formation of the complex peptide-TAR increases: Ki
6  < 5  < 7; moreover, the presence of a piperazine in the side
chain (compounds 6 and 5) has a positive effect on the activity
of compounds, probably because it confers more rigidity to the
chain  and  the  position  of  the  pyridine  ring  respect  to  the
quinolone nucleus is fixed. Even if a strict correlation between
the  Ki  values  and  the  anti-HIV  activities  did  not  exist,  this
assay confirmed that the impairment of the Tat-TAR complex
formation represents a putative target for the new derivatives.
CONCLUSION
The  Tat-mediated  transcription,  the  only  phase  of  the
HIV-1 replicative cycle  in  which viral  genome amplification
occurs, is a really attractive step that if inhibited by a suitable
inhibitor could lead to a functional cure or even HIV infection
eradication.  For  years,  the  inhibition  of  the  Tat-mediated
transcription  has  been  highly  pursued  through  different  app-
roaches,  but  this  step  of  the  viral  replicative  cycle  remains
untouched by any of the drugs in therapy. However, there are
examples  of  promising  Tat-mediated  transcription  inhibitors
worthy to be mentioned, such as triptolide [37] and dCA [38]
working on Tat protein.
In  the  attempt  to  obtain  potent  TAR  binders,  we  started
from WM5, a small molecule endowed with potent anti-HIV
and Tat-mediated transcription inhibition activity thanks to the
ability to selectively bind the bulge region of TAR; indeed no
interaction  with  TAR-unrelated  nucleic  acids  such  as  tRNA
sequence and single-stranded or double-stranded DNA struc-
tures was observed [39].
Starting  from  WM5,  various  protonable  moieties  were
inserted  in  different  positions  of  the  quinolone  scaffold,
intended to mime the basic region of Tat involved in the TAR
interaction.  The  modifications  introduced  in  the  structure  do
not  result  in  loss  of  activity,  but  rather  seem to  improve  the
activity  as  inhibitors  of  the  Tat-TAR  complex  formation,
leading  to  the  identification  of  compounds  able  to  recognize
TAR  better  than  WM5.  Important  SAR  insights  were  also
achieved  for  the  quinolone  class  of  anti-HIV  derivatives.  In
particular,  the  C-6  and  C-7  positions  were  confirmed  as
particularly sensitive to structural modifications, while the N-1
emerged as a suitable position to host protonable moieties such
as  the  pyridine-based  side  chains.  This  is  an  important  new
insight  since  the  most  potent  quinolones  reported  until  now
were all characterized by the presence of small alkyl groups at
the  N-1  position  [22,  40].  In  addition,  potent  anti-HIV com-
pounds were identified, with naphthyridone derivatives 10 and
12 which showed EC50 values in the sub-micromolar range.
In conclusion, the addition of protonable chains as tool to
improve the TAR binding properties permitted to obtain active
compounds,  but  additional  knowledge  on  the  interaction  of
TAR RNA with  viral  protein  Tat  and  host  Super  Elongation
Complex  (SEC)  [41,  42]  are  still  necessary  to  design
compounds  able  to  better  recognize  the  TAR  RNA  and
potently inhibit HIV replication. During the reviewing of this
work, two interesting papers were published that could help the
design  of  an  effective  TAR  binder.  In  particular,  Schulze-
Gahmen and Hurley solved the crystal structure of the TAR in
complex  with  Tat  and  the  SEC  core  (CycT1/CDK9/AFF4)
[43], while Varani and co-workers reported the NMR structure
of  TAR  RNA  in  complex  with  a  ultra-potent  macrocyclic
peptide  that  mimics  the  Arginine  Rich  Motif  (ARM)  of  Tat
[44],  which  however  only  weakly  inhibit  the  Tat-mediated
transcription.
These studies revealed how the direct  interaction of  Tat-
ARM with  TAR  RNA bulge  is  required  to  induce  the  RNA
structural  change,  but it  is  the recognition of the loop by the
CycT1 that dominantly contributes to the binding energy. Thus,
a future TAR binder should be able to target not only the UCU
bulge  but  above  all  the  interaction  of  CycT1  with  the
rearranged  TAR  RNA  loop,  to  achieve  an  effective  Tat-
mediated  transcription  inhibition  in  cells.
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